CRVS (Corvus Pharmaceuticals, Inc.) Stock Market Reviews

crown

search

Read and share opinions on CRVS (Corvus Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

CRVS

Corvus Pharmaceuticals, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Corvus: Q3 Earnings Snapshot
Nov 4, 2025
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Nov 3, 2025
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 31, 2025
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Oct 28, 2025
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Oct 2, 2025
Corvus: Q2 Earnings Snapshot
Aug 7, 2025
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
Jul 31, 2025
Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says
Jul 8, 2025
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Jun 25, 2025
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
Jun 11, 2025
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
May 28, 2025
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?
May 9, 2025

Reviews